Abstract
Peroxisome proliferator-activated receptor
Peroxisome proliferator-activated receptor
C. Gaudel and P. A. Grimaldi, “Metabolic functions of peroxisome proliferator-activated receptor in skeletal muscle,” PPAR Research, vol. 2007, Article ID 86394, 6 pages, 2007.
View at: Publisher Site | Google ScholarY.-X. Wang, C.-L. Zhang, and R. T. Yu et al., “Regulation of muscle fiber type and running endurance by PPAR,” PLoS Biology, vol. 2, no. 10, pp. 1532–1539, 2004.
View at: Publisher Site | Google ScholarG. D. Barish, V. A. Narkar, and R. M. Evans, “PPAR: a dagger in the heart of the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006.
View at: Publisher Site | Google ScholarC. K. Roberts and R. J. Barnard, “Effects of exercise and diet on chronic disease,” Journal of Applied Physiology, vol. 98, no. 1, pp. 3–30, 2005.
View at: Publisher Site | Google ScholarF. W. Booth and R. A. Shanely, “The biochemical basis of the health effects of exercise: an integrative view,” in Proceedings of the Nutrition Society, vol. 63, no. 2, pp. 199–203, Columbia, Mo, USA, May 2004.
View at: Publisher Site | Google ScholarT. R. Koves, P. Li, and J. An et al., “Peroxisome proliferator-activated receptor- co-activator 1-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency,” Journal of Biological Chemistry, vol. 280, no. 39, pp. 33588–33598, 2005.
View at: Publisher Site | Google ScholarA. P. Russell, J. Feilchenfeldt, and S. Schreiber et al., “Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor- coactivator-1 and peroxisome proliferator-activated receptor- in skeletal muscle,” Diabetes, vol. 52, no. 12, pp. 2874–2881, 2003.
View at: Publisher Site | Google ScholarS. Trappe, M. Harber, and A. Creer et al., “Single muscle fiber adaptations with marathon training,” Journal of Applied Physiology, vol. 101, no. 3, pp. 721–727, 2006.
View at: Publisher Site | Google ScholarE. Volpi, R. Nazemi, and S. Fujita, “Muscle tissue changes with aging,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 7, no. 4, pp. 405–410, 2004.
View at: Publisher Site | Google ScholarD. Freyssenet, “Energy sensing and regulation of gene expression in skeletal muscle,” Journal of Applied Physiology, vol. 102, no. 2, pp. 529–540, 2007.
View at: Publisher Site | Google ScholarA. Leal-Cerro, A. Gippini, and M. J. Amaya et al., “Mechanisms underlying the neuroendocrine response to physical exercise,” Journal of Endocrinological Investigation, vol. 26, no. 9, pp. 879–885, 2003.
View at: Google ScholarJ. Mercier, A. Perez-Martin, X. Bigard, and R. Ventura, “Muscle plasticity and metabolism: effects of exercise and chronic diseases,” Molecular Aspects of Medicine, vol. 20, no. 6, pp. 319–373, 1999.
View at: Publisher Site | Google ScholarA. G. Smith and G. E. O. Muscat, “Skeletal muscle and nuclear hormone receptors: Implications for cardiovascular and metabolic disease,” International Journal of Biochemistry and Cell Biology, vol. 37, no. 10, pp. 2047–2063, 2005.
View at: Publisher Site | Google ScholarD. Pette, H. Peuker, and R. S. Staron, “The impact of biochemical methods for single muscle fibre analysis,” Acta Physiologica Scandinavica, vol. 166, no. 4, pp. 261–277, 1999.
View at: Publisher Site | Google ScholarJ. He, S. Watkins, and D. E. Kelley, “Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity,” Diabetes, vol. 50, no. 4, pp. 817–823, 2001.
View at: Publisher Site | Google ScholarJ. Norrbom, C. J. Sundberg, H. Ameln, W. E. Kraus, E. Jansson, and T. Gustafsson, “PGC-1 mRNA expression is influenced by metabolic perturbation in exercising human skeletal muscle,” Journal of Applied Physiology, vol. 96, no. 1, pp. 189–194, 2004.
View at: Publisher Site | Google ScholarK. Baar, A. R. Wende, and T. E. Jones et al., “Adaptations of skeletal muscle to exercise: Rapid increase in the transcriptional coactivator PGC-1,” FASEB Journal, vol. 16, no. 14, pp. 1879–1886, 2002.
View at: Publisher Site | Google ScholarS.-H. Koo, H. Satoh, and S. Herzig et al., “PGC-1 promotes insulin resistance in liver through PPAR--dependent induction of TRB-3,” Nature Medicine, vol. 10, no. 5, pp. 530–534, 2004.
View at: Publisher Site | Google ScholarH. Liang and W. F. Ward, “PGC-1: a key regulator of energy metabolism,” Advances in Physiology Education, vol. 30, no. 4, pp. 145–151, 2006.
View at: Publisher Site | Google ScholarE. Hondares, I. Pineda-Torra, R. Iglesias, B. Staels, F. Villarroya, and M. Giralt, “PPAR, but not PPAR, activates PGC-1 gene transcription in muscle,” Biochemical and Biophysical Research Communications, vol. 354, no. 4, pp. 1021–1027, 2007.
View at: Publisher Site | Google ScholarS. Luquet, J. Lopez-Soriano, and D. Holst et al., “Peroxisome proliferator-activated receptor controls muscle development and oxidative capability,” FASEB Journal, vol. 17, no. 15, pp. 2299–2301, 2003.
View at: Publisher Site | Google ScholarP. Garcia-Roves, J. M. Huss, and D.-H. Han et al., “Raising plasma fatty acid concentration induces increased biogenesis of mitochondria in skeletal muscle,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 25, pp. 10709–10713, 2007.
View at: Publisher Site | Google ScholarR. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004.
View at: Publisher Site | Google ScholarO. Barbier, I. P. Torra, and Y. Duguay et al., “Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 5, pp. 717–726, 2002.
View at: Publisher Site | Google ScholarS. Luquet, J. Lopez-Soriano, and D. Holst et al., “Roles of peroxisome proliferator-activated receptor delta (PPAR) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome,” Biochimie, vol. 86, no. 11, pp. 833–837, 2004.
View at: Publisher Site | Google ScholarD. M. Muoio, D. B. MacLean, and D. B. Lang et al., “Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) knock-out mice. Evidence for compensatory regulation by PPAR,” Journal of Biological Chemistry, vol. 277, no. 29, pp. 26089–26097, 2002.
View at: Publisher Site | Google ScholarU. Dressel, T. L. Allen, J. B. Pippal, P. R. Rohde, P. Lau, and G. E.O. Muscat, “The peroxisome proliferator-activated receptor agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells,” Molecular Endocrinology, vol. 17, no. 12, pp. 2477–2493, 2003.
View at: Publisher Site | Google ScholarO. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996.
View at: Publisher Site | Google ScholarM. Schuler, F. Ali, and C. Chambon et al., “PGC1 expression is controlled in skeletal muscles by PPAR, whose ablation results in fiber-type switching, obesity, and type 2 diabetes,” Cell Metabolism, vol. 4, no. 5, pp. 407–414, 2006.
View at: Publisher Site | Google ScholarY.-X. Wang, C.-H. Lee, S. Tiep, R. T. Yu, J. Ham, H. Kang, and R. M. Evans, “Peroxisome-proliferator-activated receptor activates fat metabolism to prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003.
View at: Publisher Site | Google ScholarE. Barton and C. Morris, “Mechanisms and strategies to counter muscle atrophy,” Journals of Gerontology—Series A Biological Sciences and Medical Sciences, vol. 58, no. 10, pp. 923–926, 2003.
View at: Google ScholarJ. Lexell and D. Downham, “what is the effect of aging on type 2 muscle fiber?,” Journals of Neurol Science, vol. 107, no. 2, pp. 250–251, 1992.
View at: Google ScholarM. R. Deschenes, “Effects of aging on muscle fiber type and size,” Sports Medicine, vol. 34, no. 12, pp. 809–824, 2004.
View at: Google ScholarK. E. Conley, S. A. Jubrias, C. E. Amara, and D. J. Marcinek, “Mitochondrial dysfunction: impact on exercise performance and cellular aging,” Exercise and Sport Sciences Reviews, vol. 35, no. 2, pp. 43–49, 2007.
View at: Publisher Site | Google ScholarZ. Arany, N. Lebrasseur, and C. Morris et al., “The transcriptional coactivator PGC-1 drives the formation of oxidative type IIX fibers in skeletal muscle,” Cell Metabolism, vol. 5, no. 1, pp. 35–46, 2007.
View at: Publisher Site | Google ScholarC. Ling, P. Poulsen, and E. Carlsson et al., “Multiple environmental and genetic factors influence skeletal muscle PGC-1 and PGC-1 gene expression in twins,” Journal of Clinical Investigation, vol. 114, no. 10, pp. 1518–1526, 2004.
View at: Publisher Site | Google ScholarY. Kamei, H. Ohizumi, and Y. Fujitani et al., “PPAR coactivator 1/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 21, pp. 12378–12383, 2003.
View at: Google ScholarA. Oberbach, Y. Bossenz, and S. Lehmann et al., “Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes,” Diabetes Care, vol. 29, no. 4, pp. 895–900, 2006.
View at: Google ScholarG. E. O. Muscat and U. Dressel, “Cardiovascular disease and PPAR: targeting the risk factors,” Current Opinion in Investigational Drugs, vol. 6, no. 9, pp. 887–894, 2005.
View at: Google ScholarL. Cheng, G. Ding, and Q. Qin et al., “Cardiomyocyte-restricted peroxisome proliferator-activated receptor- deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy,” Nature Medicine, vol. 10, no. 11, pp. 1245–1250, 2004.
View at: Publisher Site | Google ScholarA. Planavila, R. Rodríguez-Calvo, M. Jové, L. Michalik, W. Wahli, J. C. Laguna, and M. Vázquez-Carrera, “Peroxisome proliferator-activated receptor activation inhibits hypertrophy in neonatal rat cardiomyocytes,” Cardiovascular Research, vol. 65, no. 4, pp. 832–841, 2005.
View at: Publisher Site | Google ScholarT. Takahashi, T. Tanaka, and J. Sakai, “New therapeutic target for metabolic syndrome: PPAR,” Endocrine Journal, vol. 54, no. 3, pp. 347–357, 2007.
View at: Publisher Site | Google ScholarT. Tanaka, S. Yamamoto, and H. Iwasaki et al., “Activation of peroxisome proliferator-activated receptor induces fatty acid -oxidation in skeletal muscle and attenuates metabolic syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15924–15929, 2003.
View at: Google ScholarK. C. Choi, S. Y. Lee, and H. J. Yoo et al., “Effect of PPAR- agonist on the expression of visfatin, adiponectin, and resistin in rat adipose tissue and 3T3-L1 adipocytes,” Biochemical and Biophysical Research Communications, vol. 357, no. 1, pp. 62–67, 2007.
View at: Publisher Site | Google ScholarC. Fürnsinn, T. M. Willson, and B. Brunmair, “Peroxisome proliferator-activated receptor-, a regulator of oxidative capacity, fuel switching and cholesterol transport,” Diabetologia, vol. 50, no. 1, pp. 8–17, 2007.
View at: Publisher Site | Google ScholarU. Seedorf and J. Aberle, “Emerging roles of PPAR in metabolism,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1771, no. 9, pp. 1125–1131, 2007.
View at: Publisher Site | Google ScholarY. Barak, D. Liao, and W. He et al., “Effects of peroxisome proliferator-activated receptor on placentation, adiposity, and colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 1, pp. 303–308, 2002.
View at: Publisher Site | Google ScholarM. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters, “The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR),” Toxicological Sciences, vol. 90, no. 2, pp. 269–295, 2006.
View at: Publisher Site | Google ScholarT.-C. He, T. A. Chan, B. Vogelstein, and K. W. Kinzler, “PPAR is an APC-regulated target of nonsteroidal anti-inflammatory drugs,” Cell, vol. 99, no. 3, pp. 335–345, 1999.
View at: Publisher Site | Google ScholarB. H. Park, B. Vogelstein, and K. W. Kinzler, “Genetic disruption of PPAR decreases the tumorigenicity of human colon cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2598–2603, 2001.
View at: Publisher Site | Google ScholarF. S. Harman, C. J. Nicol, H. E. Marin, J. M. Ward, F. J. Gonzalez, and J. M. Peters, “Peroxisome proliferator-activated receptor- attenuates colon carcinogenesis,” Nature Medicine, vol. 10, no. 5, pp. 481–483, 2004.
View at: Google ScholarH. E. Marin, M. A. Peraza, and A. N. Billin et al., “Activation of peroxisome proliferator-activated receptor inhibits colon carcinogenesis,” Cancer Research, vol. 66, no. 8, pp. 4394–4401, 2006.
View at: Publisher Site | Google ScholarR. L. Stephen, M. C. U. Gustafsson, and M. Jarvis et al., “Activation of peroxisome proliferator-activated receptor stimulates the proliferation of human breast and prostate cancer cell lines,” Cancer Research, vol. 64, no. 9, pp. 3162–3170, 2004.
View at: Google ScholarL. Xu, C. Han, and T. Wu, “A novel positive feedback loop between peroxisome proliferator-activated receptor- and prostaglandin signaling pathways for human cholangiocarcinoma cell growth,” Journal of Biological Chemistry, vol. 281, no. 45, pp. 33982–33996, 2006.
View at: Publisher Site | Google ScholarA. Erol, “Insulin resistance is an evolutionarily conserved physiological mechanism at the cellular level for protection against increased oxidative stress,” BioEssays, vol. 29, no. 8, pp. 811–818, 2007.
View at: Publisher Site | Google Scholar